$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of JFB Construction Holdings (NASDAQ: JFB) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Class Action Attorney [Juan Monteverde] with [Monteverde & Associates PC](the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York Ci ...

GoDaddy ANS Integrates with Salesforce's MuleSoft Agent Fabric [Accessibility Statement] Skip NavigationThe solution helps organizations discover AI agents and confirm identity to reduce the risk of spoofed toolsTEMPE, Ariz., Feb. 19, 2026 /PRNewswire/ -- GoDaddy (NYSE: GDDY) today announced an integration with Salesforce's MuleSoft Agent Fabric that helps companies of all sizes discover AI agents and verify their identity. This helps prevent rogue agents from interacting with business systems and sensitive ...

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]

Warner Bros. Discovery to Report Fourth Quarter and Full Year 2025 Results on Thursday, February 26 [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Warner Bros. Discovery, Inc. (the "Company") (Nasdaq: WBD) today announced that it will report its fourth quarter and full year 2025 results on Thursday, February 26, 2026 before the market opens. Links to the live webcast of the conference call as well as the earnings materials will be available in the "Investor Relations" secti ...

Chubb Appoints Scott Henck Global Chief Actuary [Accessibility Statement] Skip NavigationCynthia Bentley promoted to succeed Henck as North America Chief Actuary; Paul O'Connell to RetireZURICH, Feb. 19, 2026 /PRNewswire/ -- Chubb Limited (NYSE: CB) today announced that Scott Henck, Executive Vice President and Chief Actuary, North America, has been appointed Senior Vice President, Chubb Group and Chief Actuary. He succeeds Paul O'Connell, who is retiring after a 40-year career in the property and casualty ...

 Mission in the 'Convoy' Campaign[Second mission in the Jeep® brand's Gladiator "Convoy" campaign, following Shadow Ops Heritage-theme, two-tone execution inspired by Jeep brand...]### Jeep® Brand's 'Billy Goes to the River' Takes No. 1 Automotive Spot on YouTube AdBlitz Leaderboard["Billy Goes to the River" was named the top automotive performer for YouTube AdBlitz 2026, with the commercial rising to the top based on a...][More Releases From This Source]## Explore[Automotive][General Sports][Sporting Even ...

Core Viewpoint - Republic Power Group Limited announced a 1-for-20 reverse share split for its Class A and Class B ordinary shares, effective February 23, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1]. Group 1: Reverse Share Split Details - The reverse share split will adjust the Class A Ordinary Shares' par value from $0.000625 to $0.0125 per share, with trading on Nasdaq continuing under the symbol "RPGL" [1]. - The number of issued and outstanding Class A Ordinary Shares will decrease from 62,025,000 to approximately 3.1 million shares, subject to adjustments for fractional shares [1]. - No fractional shares will be issued; all fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares [1]. Group 2: Company Background - Republic Power Group Limited is based in Singapore and specializes in developing customized enterprise resource planning (ERP) software solutions, consulting, technical support services, and peripheral hardware [1].

Core Insights - Clearmind Medicine is advancing its proprietary compound MEAI, a non-hallucinogenic neuroplastogen, as a potential next-generation treatment for obesity, targeting the psychological roots of eating behaviors [1] - The obesity treatment market is projected to exceed $100 billion, indicating significant growth potential for innovative therapies like MEAI [1] Company Overview - Clearmind Medicine is a clinical-stage biotech company focused on developing novel therapeutics to address under-treated health issues, particularly obesity [1] - MEAI is designed to disrupt rigid behavioral patterns, promote cognitive flexibility, and enhance neuronal plasticity while providing metabolic benefits [1] Mechanism of Action - Unlike GLP-1-based treatments that primarily target gut hormones, MEAI works directly in the brain by modulating the monoaminergic system, addressing compulsive eating behaviors and food addiction [1] - Pre-clinical studies indicate that MEAI can modulate energy balance, boost fat burning, improve insulin sensitivity, and significantly decrease fat mass while preserving lean muscle mass [1] Comparative Analysis - MEAI shows a potential weight loss profile of approximately 20% reduction in pre-clinical studies, prioritizing fat loss and muscle preservation, compared to GLP-1 drugs which show a 15-22% reduction often accompanied by muscle loss [1] - MEAI has a favorable safety profile with no reported sedation or hyperactivity, contrasting with common gastrointestinal issues associated with GLP-1 drugs [1] Strategic Developments - Clearmind has filed new patent applications targeting obesity and metabolic disorders and is collaborating with Polyrizon to develop an intranasal formulation for enhanced delivery [1] - The company is progressing in its FDA-approved Phase I/IIa trial for alcohol use disorder, with successful cohort completions and upcoming data readouts [1] Future Outlook - Clearmind's leadership emphasizes MEAI's potential as a safer, more effective alternative to current therapies, focusing on behavioral aspects of obesity that hormonal drugs often overlook [1] - The combination of pre-clinical and clinical evidence, intellectual property advancements, and strategic partnerships positions MEAI as a promising solution for sustainable weight management [1]

Approval of FIS Bright Portfolios Focused Equity ETF Reorganization [Accessibility Statement] Skip NavigationSCOTTSDALE, Ariz., Feb. 19, 2026 /PRNewswire/ -- FIS Bright Portfolios Focused Equity ETF (NYSE: BRIF) ("BRIF" or the "Fund") reconvened a special meeting of shareholders earlier today (the "Special Meeting"). At the Special Meeting, the Fund's shareholders were asked to approve an Agreement and Plan of Reorganization pursuant to which BRIF will be reorganized into FIS Trust, as approved by BRIF's Bo ...

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Summary by Relevant Sections Class Action Lawsuit Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx and its executives made false statements and failed to disclose critical information about the Phase III Orbit study, which did not achieve statistically significant results [1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a false impression of having reliable data on setrusumab's effects while downplaying the risks associated with the Phase III Orbit study [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study failed to achieve statistical significance, leading to a stock price drop of over 25% [1] - Further, on December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies did not meet primary endpoints, resulting in a stock price decline of more than 42% [1] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek lead plaintiff status, representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1]